Adagio Medical is a technology company.
Adagio Medical is a technology company.
Adagio Medical has raised $43.0M across 1 funding round.
Adagio Medical has raised $43.0M in total across 1 funding round.
Adagio Medical has raised $43.0M in total across 1 funding round.
Adagio Medical's investors include RA Capital.
Adagio Medical is a medical device company specializing in the development of advanced cryoablation technologies to treat cardiac arrhythmias such as atrial fibrillation, atrial flutter, and ventricular tachycardia. Its flagship product leverages proprietary Ultra Low Temperature Cryoablation (ULTC) technology designed to create large, durable lesions that extend through the full thickness of cardiac tissue, improving treatment efficacy. The company primarily serves cardiologists and electrophysiologists by providing innovative tools to address complex heart rhythm disorders, aiming to improve patient outcomes and procedural efficiency[1][4][5][6].
Founded in 2020 and headquartered in Laguna Hills, California, Adagio Medical emerged from the need for more effective and durable ablation solutions in cardiac care. The company quickly gained traction by advancing its ULTC technology into clinical and commercial stages, including regulatory approvals and market introduction in the European Union. This early progress positioned Adagio as a promising innovator in the cardiac ablation space[1][3][4].
Adagio Medical is riding the trend of increasing demand for minimally invasive, effective cardiac arrhythmia treatments driven by the rising prevalence of atrial fibrillation and other rhythm disorders globally. Advances in cryoablation technology align with broader healthcare trends emphasizing precision medicine and improved patient safety. The timing is favorable due to growing awareness of arrhythmia-related morbidity and healthcare systems seeking cost-effective interventions. Adagio’s innovations contribute to evolving electrophysiology practices and may influence standards of care by offering an alternative to traditional ablation techniques[1][4][6].
Looking ahead, Adagio Medical is poised to expand its market presence by advancing clinical evidence, pursuing additional regulatory clearances, and broadening its product portfolio. Trends such as an aging population and increasing incidence of cardiac arrhythmias will likely drive demand for its technologies. The company’s ability to demonstrate superior clinical outcomes and cost-effectiveness will be critical to its influence and growth in the cardiac device sector. Continued innovation in cryoablation could position Adagio as a key player shaping the future of cardiac arrhythmia treatment[1][4][6].
Adagio Medical has raised $43.0M across 1 funding round. Most recently, it raised $43.0M Series E in November 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2020 | $43.0M Series E | RA Capital |